ArticleGland surgery2026
Factors influencing postoperative thyroid-stimulating hormone suppression therapy in low-risk papillary thyroid cancer after lobectomy.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid-stimulating hormone (TSH) suppression therapy remains an important treatment option for patients with low-risk differentiated thyroid cancer (DTC). This study aimed to analyze the potential influencing factors affecting TSH suppression outcomes in patients with postoperative low-risk papillary thyroid cancer (PTC). Methods: A total of 223 low-risk PTC patients were enrolled in this single-center cross-sectional study between September 2024 and February 2025. Based on the TSH level measured at 4-6 months post-lobectomy, the patients were divided into three groups: an excessive TSH suppression group (TSH <0.5 mU/L), optimal TSH suppression group (TSH 0.5-2.0 mU/L), and insufficient TSH suppression group (TSH >2.0 mU/L). The clinicopathological data of the patients, including demographic, clinical laboratory, pathological, and lifestyle characteristics, were analyzed to investigate the factors influencing TSH suppression therapy. Results: There were no statistically significant differences in age, marital status, preoperative free triiodothyronine (FT3), free thyroxine (FT4), thyroglobulin antibody (TG-Ab), thyroid peroxidase antibody (TPO-Ab), thyroglobulin (Tg) level, longest tumor diameter, lesion site, central lymph node metastasis, Hashimoto's thyroiditis, Conclusions: A complex interplay exists among demographic, clinical, and lifestyle factors in postoperative TSH management. Prospective studies with objective lifestyle measurements are needed to confirm these associations before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.